This study used data from a multinational phase III randomized, double-blind, 
vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad 
mesylate (Freedox) in the treatment of aneurysmal subarachnoid hemorrhage. In 
men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with 
significantly increased survival, increased cost of care, and ratios of cost per 
death averted that compare favorably with the ratios of other life and death 
interventions. In women, it appeared to have no effects on costs or survival. 
Further clinical studies may provide additional information about the 
cost-effectiveness of this intervention.